KEW Group LLC provides DNA based genomic testing and interpretation services with evidence-based diagnostic and treatment pathways to oncology practices. The company offers Therapeutic Pathways, a platform for personalized medicine, which provides information about current and emerging therapies, and is deployed in Web-based format for oncology practitioners and other healthcare workers; and KEW CancerPlexSM symbol, a gene testing panel to evaluate genetic changes in a patient's tumor to help oncologists manage treatment options. It also provides molecular genetic testing services, which determine whether a particular individual is at risk to develop certain types of cancers or examination o...
790 Memorial Drive
Cambridge, MA 02139
Founded in 2009
Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists
Sep 29 14
Cardinal Health Specialty Solutions and KEW Group Inc. announced an agreement for the two companies to make KEW's diagnostic services available to Specialty Solutions' community oncology customers. Cardinal Health Specialty Solutions customers will now have access to KEW's CancerPlex. CancerPlex: Simultaneously provides complete sequence coverage of more than 410 cancer genes; Simplifies and streamlines the test-ordering process by eliminating serial "hotspot" tests; Delivers a comprehensive report, including actionable data; Informs physicians of optimal treatment options using approved therapies and available clinical trials; and Supports clinical trial enrollment by providing oncologists with required molecular data.
KEW Group Inc. Appoints Scott Schell, MD, MBA, PhD as New President and CEO, Effective July 1, 2014
Jun 16 14
KEW Group Inc. announced the appointment of Scott Schell, MD, MBA, PhD, as KEW's new President and Chief Executive Officer. KEW is focused on revolutionizing cancer care by empowering oncologists to access and apply genomic insights to design optimal, individualized treatment approaches for patients. Dr. Schell, who will also become a member of KEW's Board of Directors, will commence his position at the company effective July 1, 2014. Most recently, Dr. Schell was instrumental in assisting the Cleveland Clinic in developing its strategy for population health management. Dr. M. Kathleen Behrens Wilsey, KEW's current CEO and a founder of the company, will remain a member of the Board of Directors of KEW Group, following Dr. Schell's transition to CEO.
KEW Group Secures Round of Financing
Feb 24 14
KEW Group Inc. secured private round of financing from Cardinal Health Inc. and The Bolyston Street Group. Leerink Partners LLC acted as placement agent for the transaction.